Inhibikase Therapeutics Statistics
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.94-0.04 (-2.02%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 1.94 0.00%
Inhibikase Therapeutics by the numbers
Inhibikase Therapeutics has a market capitalization of $270.7 million based on 139.54M shares outstanding. With trailing EPS of $-0.43, Inhibikase Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 16.1% below its 50-day average and 0.3% below its 200-day average.
Average daily trading volume is 665.95K shares, or about $1.3 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
IKT valuation vs. peer median
| Metric | IKT | Peer median | Difference |
|---|---|---|---|
| Market cap | $270.70M | $259.98M | +4% |
| Avg. volume | 665.95K | 995.76K | -33% |
Peer median across 8 companies: XFOR, LXEO, SABS, PALI, FATE, SRZN, STRO, LCTX.
Valuation
- Market cap
- $270.70M
- EPS (TTM)
- $-0.43
- Shares outstanding
- 139.54M
Price and trading
- Previous close
- 1.98
- Open
- 1.95
- Day range
- 1.93 – 2.00
- 52-week range
- 1.33 – 2.61
- Beta
- —
- Volume
- 444.05K
- Average volume
- 665.95K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 13, 2026
Additional statistics
- Market Cap
- 270.70M
- Forward Pe
- -4.49
- Eps
- -0.43
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 2.61
- Week52 Low
- 1.33
- Avg Volume
- 665.95K
- Shares Outstanding
- 139.54M
- Ma50
- 2.31
- Ma200
- 1.95
- Earnings Date
- Nov 13, 2026
- Pct From52w High
- -25.67%
- Pct From52w Low
- 45.86%